Type: Oral
Session: 722. Allogeneic Transplantation: Acute and Chronic GVHD and Immune Reconstitution: Monitoring, Understanding and Optimizing GVHD Interventions
Hematology Disease Topics & Pathways:
Research, Translational Research, Treatment Considerations, Biological therapies, Adverse Events, Technology and Procedures, Transplantation (Allogeneic and Autologous), Omics technologies
PD-1 is a coinhibitory receptor that attenuates the activation and function of effector T cells. However, the role of PD-1 on CD4Treg is not fully understood. LD IL-2 therapy induces expression of PD-1 on CD4Treg, and PD-1 has a critical role in maintaining CD4Treg expansion during LD IL-2 treatment (Asano T et al, Blood 2017). This prompted us to conduct a detailed analysis of PD-1+CD4Treg and their relevance to clinical outcomes after LD IL-2 therapy.
Methods. To identify intrinsic Treg factors associated with clinical outcome, we analyzed serial cryopreserved PBMC samples from 21 patients with steroid-refractory cGVHD who were enrolled in a clinical trial combining extracorporeal photopheresis (ECP) and LD IL-2 therapy. Phenotypic changes in PBMC during treatment were monitored by mass cytometry. To elucidate CD4Treg heterogeneity, we also used single-cell RNA sequencing to characterize CD4Treg (CD3+CD4+CD25+CD127low) derived from cryopreserved PBMC of responders (n = 4) and non-responders (n = 6) four weeks after initiation of LD IL-2.
Results. ECP therapy alone had minimal impact on CD4Treg, but additional treatment with LD IL-2 markedly altered multiple CD4Treg populations, including a PD-1+CD4Treg cluster characterized as highly activated, immune suppressive, and proapoptotic. This effect was also observed in CD4Treg from healthy individuals stimulated with LD IL-2 alone in vitro. After in vitro LD IL-2 stimulation, PD-1+CD4Treg suppressed the proliferation of effector T cells more effectively than PD-1-CD4Treg. Although PD-1+CD4Treg clusters increased from baseline in clinical responders, the increase of PD-1+CD4Treg clusters was not different between responders and non-responders.
Unsupervised clustering of single-cell RNAseq data identified six distinct groups of CD4Treg, including a naïve-like subset (PDCD1-low with high expression of CCR7, TCF7, and LEF1), an exhausted subset (PDCD1+ with high expression of LAG3, CTLA4, and TIGIT), and an effector subset (PDCD1+ with high expression of CCR4 and IKZF2). The exhausted CD4Treg subset also featured expression of cytotoxicity markers (NKG7, GZMA, and GZMK). When comparing LD IL-2 responders to non-responders, we found that the ratio of effector/exhausted Treg was significantly higher in patients with clinical response (p = 0.019).
To further explore differences within CD4Treg associated with clinical improvement of cGVHD, we performed pseudo-bulk differential gene expression analyses. We found that there were many individual genes whose expression was significantly associated with clinical response, particularly in an effector CD4Treg subset in non-responders. Gene set enrichment analysis revealed that pathways related to cytokine signaling, including interferon (STAT1, IFNGR2, IRF1, SOCS1, and SOCS3), were enriched in non-responders in multiple CD4Treg subsets. In responders, IFITM3 was upregulated among the effector and exhausted CD4Treg cells; this gene was recently reported as a negative feedback regulator of the IFNg-induced STAT1 pathway in CD4Treg. These results suggest that activation of the IFNg-induced STAT1 pathway in CD4Treg may have promoted expansion of more exhausted CD4Treg in clinical non-responders.
Conclusions. In summary, LD IL-2 therapy in patients with cGVHD induced multiple CD4Treg populations, including PD-1+CD4Tregs. However, PD-1+CD4Tregs are heterogeneous, including both exhausted and effector subsets, and the balance between these two CD4Treg subsets after IL-2 therapy appears to correlate with clinical improvement after LD IL-2 therapy. Additionally, activation of the STAT1 pathway is one of the putative CD4Treg-intrinsic factors associated with lack of clinical response to LD IL-2 therapy. Validation studies and functional assays are ongoing.
Disclosures: Livak: MBQ Pharma Inc.: Membership on an entity's Board of Directors or advisory committees. Freeman: Geode: Consultancy, Current equity holder in private company, Current holder of stock options in a privately-held company; Simcere of America: Consultancy; Santa Ana Bio: Consultancy; Bioentre: Consultancy, Current equity holder in private company; IOME: Consultancy; GV20: Consultancy, Current equity holder in private company, Current holder of stock options in a privately-held company; IgM: Consultancy, Current equity holder in publicly-traded company; Nextpoint: Consultancy, Current equity holder in private company, Current holder of stock options in a privately-held company; iTEOS: Consultancy, Current equity holder in publicly-traded company; Novartis: Patents & Royalties: PD-L1/PD-1 pathway; Eli Lilly: Patents & Royalties: PD-L1/PD-1 pathway; Leica: Patents & Royalties: PD-L1/PD-1 pathway; Dako: Patents & Royalties: PD-L1/PD-1 pathway; Boehringer-Ingelheim: Patents & Royalties: PD-L1/PD-1 pathway; Merck MSD: Patents & Royalties: PD-L1/PD-1 pathway; Bristol-Myers Squibb: Patents & Royalties: PD-L1/PD-1 pathway; AstraZeneca: Patents & Royalties: PD-L1/PD-1 pathway; Merck KGA: Patents & Royalties: PD-L1/PD-1 pathway; Roche: Patents & Royalties: PD-L1/PD-1 pathway; Invaria: Current equity holder in private company, Membership on an entity's Board of Directors or advisory committees. Whangbo: Vor Biopharma: Current Employment. Shapiro: Miltenyi: Other: Paid lecture; Hansa Biopharma: Consultancy. Gooptu: Syndax: Consultancy, Other: Travel expenses. Romee: CRISPR Therapeutics: Research Funding; Skyline Therapeutics: Research Funding; Glycostem: Membership on an entity's Board of Directors or advisory committees. Ho: Alexion: Consultancy; Omeros: Research Funding; CareDx: Research Funding; Jazz: Research Funding; Allovir: Consultancy. Cutler: Oxford Immune Algorithmics: Current equity holder in private company; Astellas: Consultancy; Cimeio: Current equity holder in publicly-traded company; Sanofi: Consultancy; Incyte: Consultancy; Angiocrine: Other: DSMB; Novartis: Consultancy; Rigel: Consultancy; Allovir: Other: DSMB; Syndax: Consultancy. Soiffer: Neovii: Consultancy; Jasper: Consultancy; Smart Immune: Consultancy; Bristol Myers Squibb: Membership on an entity's Board of Directors or advisory committees; Vor Biopharma: Consultancy; Amgen: Consultancy; Astellas: Consultancy. Koreth: Biopharm Communications LLC: Honoraria; Tr1X Inc: Consultancy; Cugene Inc: Membership on an entity's Board of Directors or advisory committees; Mallinckrodt Inc: Membership on an entity's Board of Directors or advisory committees; Clinigen Labs Inc: Research Funding; Iovance Inc: Research Funding; Equillium Inc: Consultancy, Membership on an entity's Board of Directors or advisory committees; Gentibio Inc: Consultancy; Biolojic Design Inc: Consultancy; Cue Biopharma Inc: Consultancy; Miltenyi Biotec GMBH: Research Funding; Regeneron Inc: Research Funding; BMS Inc: Research Funding; CSL Behring Inc: Consultancy. Wu: Repertoire: Membership on an entity's Board of Directors or advisory committees; Pharmacyclics: Research Funding; BioNtech, Inc: Current equity holder in publicly-traded company; Adventris: Membership on an entity's Board of Directors or advisory committees; Aethon Therapeutics: Membership on an entity's Board of Directors or advisory committees. Ritz: Kite/Gilead: Research Funding; Novartis: Research Funding; Oncternal: Research Funding; Oncternal: Research Funding; Clade Therapeutics: Membership on an entity's Board of Directors or advisory committees; Garuda Therapeutics: Membership on an entity's Board of Directors or advisory committees; LifeVault Bio: Membership on an entity's Board of Directors or advisory committees; Smart Immune: Membership on an entity's Board of Directors or advisory committees; TriArm Bio: Membership on an entity's Board of Directors or advisory committees.
See more of: Oral and Poster Abstracts